UCB (STU:UNC) Operating Margin %: 30.18% (As of Dec. 2025) — 36% Above Median


STU:UNC UCB SA STU:UNC
89 GF Score
Price €254.10
GF Value €212.78
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB Operating Margin %?

UCB STU:UNC +0.99% 89 Operating Margin % is 30.18% as of Dec. 2025, which is 36% above its 10-year median of 22.16. GuruFocus rates STU:UNC with a GF Score™ of 89/100 and a GF Value™ of €212.78 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, UCB ranks better than 91.43% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. UCB's Operating Income for the six months ended in Dec. 2025 was €1,284 Mil. UCB's Revenue for the six months ended in Dec. 2025 was €4,254 Mil. Therefore, UCB's Operating Margin % for the quarter that ended in Dec. 2025 was 30.18%.

The historical rank and industry rank for UCB's Operating Margin % or its related term are showing as below:

STU:UNC' s Operating Margin % Range Over the Past 10 Years
Min: 12.05   Med: 22.16   Max: 25.89
Current: 25.89


STU:UNC's Operating Margin % is ranked better than
91.43% of 945 companies
in the Biotechnology industry
Industry Median: -86.89 vs STU:UNC: 25.89

UCB's 5-Year Average Operating Margin % Growth Rate was -0.40% per year.

UCB's Operating Income for the six months ended in Dec. 2025 was €1,284 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €2,004 Mil.


UCB  (STU:UNC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


UCB Operating Margin % Related Terms


UCB Operating Margin % Historical Data

* Premium members only.

The historical data trend for UCB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Operating Margin % Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.88 12.71 12.05 13.75 25.89

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.63 11.97 15.23 20.65 30.18

STU:UNC vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, UCB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where UCB's Operating Margin % falls into.


STU:UNC
89GF Score
UCB SA STU:UNC
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

UCB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=2004 / 7741
=25.89 %

UCB's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=1284 / 4254
=30.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 30.18% mean?
UCB (STU:UNC) has a Operating Margin % of 30.18% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on UCB and its competitors. This is 36% above median its historical median of 22.16. Over the past decade, UCB's Operating Margin % has ranged from 12.05 to 25.89. According to the industry distribution chart, UCB ranks #81 out of 945 companies in the Biotechnology industry, placing it in the top 8.6%.
Is UCB's Operating Margin % too high?
UCB's current Operating Margin % of 30.18% is 36% above median its 10-year median of 22.16. Over the past 10 years, this metric has ranged from a low of 12.05 to a high of 25.89. Based on the distribution chart, UCB ranks #81 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #81 out of 945 companies for Operating Margin %. This places UCB in the top 9% of its industry — outperforming the majority of peers. Historically, UCB's own Operating Margin % has ranged from 12.05 to 25.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on UCB and its competitors. UCB's current Operating Margin % is 30.18%, which is 36% above median its own 10-year median of 22.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €212.78, compared to a current price of €254.10 — trading 19.4% above its estimated fair value. The current Operating Margin % is 30.18%, which is 36% above median its 10-year median of 22.16. UCB's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For UCB (STU:UNC), the current Operating Margin % is 30.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €254.10 is trading 19.4% above its estimated GF Value™ of €212.78. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Operating Margin %: 30.18% (36% above median its 10-year median of 22.16)
  • GF Value™: €212.78 vs. price of €254.10 (19.4% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for STU:UNC

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€254.10
Price
€212.78
GF Value